Deloitte launches MyPath platform: ‘A digital partner in care’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Vasyl Dolmatov)
(Image: Getty/Vasyl Dolmatov)

Related tags: Deloitte, Telemedicine

ConvergeHealth by Deloitte has launched a new platform for the health care ecosystem that provides clinical trial participants and patients with personalized support and connection to their care teams.

MyPath for Health specifically connects patients, caregivers, providers, and life sciences organizations, while MyPath for Connected Care provides virtual care services.

Together, the platforms bring together patients and care teams across the entire patient journey, including clinical trials and treatment.

“When used for clinical trials, MyPath gives patients personalized support and information and connects them directly to their care teams,”​ Christopher Zant, principal, Deloitte Consulting, and chief digital officer, ConvergeHealth by Deloitte, told us.

MyPath for Health delivers care coordination and provides medication and appointment reminders via a 24/7 support network, while enabling remote health and risk monitoring, among other capabilities.

“It can become a digital partner in care,”​ Zant added, “providing a support network to reduce the patient burden of participating in clinical trials so they can focus on their health.”

The solution collates data from various sources, such as electronic health records (EHRs) and wearables, into a single platform. It also provides integrated analytics capabilities, said Zant, “so patients can share more data with their care teams without increased manual efforts and/or the opportunity for mistakes.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more